Table 2. Immunocytochemical demonstration of NESP55 and CgA in 118 endocrine and nonendocrine tumours.
| Tumour type | Case no. | NESP55 | CgA |
|---|---|---|---|
| Ileal endocrine tumours | (1–15) | 0/15(15, 0, 0, 0) | 15/15(0, 0, 0, 15) |
| Pancreatic endocrine tumours | (16–40) | 14/25 (11, 6, 3, 5) | 25/25 (0, 0, 2, 23) |
| Neuroblastomas | (41–54) | 7/14 (7, 6, 1, 0) | 14/14 (0, 0, 1, 13) |
| Pheochromocytomas | (55–73) | 19/19 (0, 1, 2, 16) | 19/19 (0, 0, 0, 19) |
| Adrenocortical adenomas | (74–88) | 0/15 (15, 0, 0, 0) | 0/15 (15, 0, 0, 0) |
| Gastric carcinomas | (89–94) | 1/6 (5, 1, 0, 0) | 0/6 (6, 0, 0, 0) |
| Colorectal carcinomas | (95–103) | 0/9 (9, 0, 0, 0) | 0/9 (9, 0, 0, 0) |
| Pancreatic carcinomas | (104–118) | 1/15 (14, 1, 0, 0) | 0/15 (15, 0, 0, 0) |
The results are given as the number of positive tumours/total number of tumours (in bold). Tumours were divided into four categories, and the number of tumours in each category is given in parentheses (0, 1+, 2+, 3+). The categories were as follows: 0 <1% positive cells, 1+=1–24% positive cells, 2+=25–75% positive cells, 3+=>75% positive cells.